Skip to main content

Table 1 Baseline demographics and disease characteristics

From: Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study

  Etanercept 50 mg/etanercept 50 mg (n= 42) Placebo/etanercept 50 mg (n= 48)
Baseline patient characteristics
Age (years) 38.8 (12.3) 38.9 (11.4)
Female 18 (42.9%) 16 (33.3%)
White 40 (95.2%) 48 (100.0%)
Weight (kg) 73.8 (14.2) 75.4 (15.2)
Body mass index (kg/m2) 25.7 (4.8) 25.9 (4.9)
Human leukocyte antigen-B27–positive 28 (66.7%) 31 (64.6%)
Disease characteristics
Duration since diagnosis of ankylosing spondylitis (years) 6.0 (9.0) 5.5 (7.4)
Past history or present symptoms   
 Arthritis 11 (26.2%) 18 (37.5%)
 Inflammatory back pain 40 (95.2%) 48 (100.0%)
 Enthesitis 25 (59.5%) 33 (68.8%)
 Dactylitis 4 (9.5%) 8 (16.7%)
 Psoriasis 9 (21.4%) 9 (18.8%)
 Uveitis 5 (11.9%) 3 (6.3%)
Family history   
 Ankylosing spondylitis 9 (21.4%) 4 (8.3%)
 Rheumatoid arthritis 2 (4.8%) 3 (6.3%)
 Inflammatory bowel disease 2 (4.8%) 1 (2.1%)
 Uveitis 2 (4.8%) 0 (0%)
Positive pelvic X-ray 24 (57.1%) 27 (56.3%)
MRI sacroiliitis positive 21 (50.0%) 24 (50.0%)
NSAID intake
ASAS-NSAID scorea 98.2 (39.0) 93.0 (23.4)
Disease activity
BASDAI (0 to 100) 6.0 (1.6) 5.9 (1.5)
ASDAS-CRP 3.4 (0.9) 3.2 (0.8)
ASDAS-CRP disease stateb   
 Inactive disease 0 (0%) 0 (0%)
 Moderate disease activity 5 (11.9%) 3 (7.0%)
 High disease activity 19 (45.2%) 23 (53.5%)
 Very high disease activity 18 (42.9%) 17 (39.5%)
PGA of disease activity (0 to 10) 6.4 (1.5) 6.2 (1.3)
Total back pain (0 to 100) 6.7 (1.7) 6.4 (1.8)
BASFI (0 to 100) 5.2 (2.1) 5.1 (2.2)
BASMI (0 to 10) 2.6 (1.8) 2.6 (1.6)
C-reactive protein level (mg/dl) 1.0 (1.3) 0.9 (1.4)
Normal C-reactive protein levelc 21 (50.0%) 28 (65.1%)
  1. Safety population; data presented as mean (standard deviation) or n (%).ASAS, Assessment of SpondyloArthritis International Society; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score on the basis of C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Function Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; MRI, magnetic resonance imaging; NSAID, nonsteroidal anti-inflammatory drug; PGA, Physician Global Assessment. aLast observation carried forward, with imputation, intent-to-treat population. bInactive disease = ASDAS-CRP <1.3; moderate disease activity = 1.3 ≤ ASDAS-CRP <2.1; high disease activity = 2.1 ≤ ASDAS-CRP <3.5; very high disease activity = ASDAS-CRP ≥3.5. cNormal CRP = ≤1.25 × the upper limit of normal (4.9 mg/l).
\